Oxford BioDynamics Plc
OXBOF · OTC
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | -0.17 | 0.02 |
| FCF Yield | -62.64% | -97.10% | -53.24% | -680.80% |
| EV / EBITDA | -1.60 | -1.46 | -1.84 | -0.89 |
| Quality | ||||
| ROIC | -95.84% | -104.04% | -69.19% | -76.34% |
| Gross Margin | -754.84% | 45.44% | 52.16% | 75.32% |
| Cash Conversion Ratio | 0.66 | 0.85 | 0.73 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.01% | 60.44% | 14.36% | -30.36% |
| Free Cash Flow Growth | 27.40% | -19.50% | -48.24% | 32.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | -0.38 | -0.12 | -0.76 |
| Interest Coverage | -26.24 | -57.31 | -47.74 | -44.11 |
| Efficiency | ||||
| Inventory Turnover | 49.94 | 1.08 | 0.89 | 0.11 |
| Cash Conversion Cycle | 251.86 | 130.07 | -261.24 | -4,966.30 |